Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma

Br J Haematol. 2015 Feb;168(4):606-10. doi: 10.1111/bjh.13132. Epub 2014 Oct 8.

Authors

Daniel A Heinrich¹, Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Vindi Jurinovic, Wolfgang Hiddemann, Martin Dreyling

Affiliation

¹ Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany; Helmholtz Zentrum München - German Research Center for Environmental Health, München, Germany. daniel.heinrich@med.uni-muenchen.de.

PMID: 25292485
DOI: 10.1111/bjh.13132

No abstract available

Keywords: anti-CD20; mantle cell lymphoma; monoclonal antibodies; obinutuzumab; rituximab.

Publication types

Comparative Study
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / immunology
Antibodies, Monoclonal, Humanized / pharmacology*
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / immunology
Antibodies, Monoclonal, Murine-Derived / pharmacology*
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antibody Specificity
Antigens, CD20 / immunology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Line, Tumor
Drug Synergism
Gene Expression Regulation, Neoplastic / drug effects*
Humans
In Vitro Techniques
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / pathology
Neoplasm Proteins / biosynthesis
Neoplasm Proteins / genetics
Rituximab

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Neoplasm Proteins
Rituximab
obinutuzumab